์ฝ˜ํ…์ธ ๋กœ ๊ฑด๋„ˆ๋›ฐ๊ธฐ
Merck

17-10400

Anti-phospho-MLKL (Ser358) Antibody Set

from rabbit, purified by affinity chromatography

๋™์˜์–ด(๋“ค):

Mixed lineage kinase domain-like protein, MLKL

์กฐ์ง ๋ฐ ๊ณ„์•ฝ ๊ฐ€๊ฒฉ์„ ๋ณด๋ ค๋ฉด ๋กœ๊ทธ์ธ๋ฅผ ํด๋ฆญํ•ฉ๋‹ˆ๋‹ค.

ํฌ๊ธฐ ์„ ํƒ


์ œํ’ˆ์ •๋ณด (DICE ๋ฐฐ์†ก ์‹œ ๋น„์šฉ ๋ณ„๋„)

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Clone:
polyclonal
Species reactivity:
human
Application:
WB
Citations:
3
๊ธฐ์ˆ  ์„œ๋น„์Šค
๋„์›€์ด ํ•„์š”ํ•˜์‹ ๊ฐ€์š”? ์ €ํฌ ์ˆ™๋ จ๋œ ๊ณผํ•™์ž ํŒ€์ด ๋„์™€๋“œ๋ฆฌ๊ฒ ์Šต๋‹ˆ๋‹ค.
๋„์›€ ๋ฌธ์˜
๊ธฐ์ˆ  ์„œ๋น„์Šค
๋„์›€์ด ํ•„์š”ํ•˜์‹ ๊ฐ€์š”? ์ €ํฌ ์ˆ™๋ จ๋œ ๊ณผํ•™์ž ํŒ€์ด ๋„์™€๋“œ๋ฆฌ๊ฒ ์Šต๋‹ˆ๋‹ค.
๋„์›€ ๋ฌธ์˜

biological source

rabbit

antibody form

purified antibody

antibody product type

primary antibodies

clone

polyclonal

purified by

affinity chromatography

species reactivity

human

technique(s)

western blot: suitable

UniProt accession no.

shipped in

wet ice

target post-translational modification

phosphorylation (pSer358)

Quality Level

Gene Information

human ... MLKL(197259)

General description

Mixed lineage kinase domain-like protein (MLKL) is required for the execution of programmed necrosis. MLKL is a cell-permeable acrylamide compound that inhibits human, but not murine, MLKL adaptor function via covalent modification of Cys86. MLKL prevents the MLKL-RIP1-RIP3 necrosome complex from interacting with further downstream effectors.
This phospho-MLKL (Ser358) antibody set contains one vial of phospho-MLKL (Ser358) antibody and one vial of MLKL โ€œTotalโ€ antibody.

RECOMMENDED USAGE:
It is recommended to first perform immunoprecipitation on your sample using the non-phosphorylated MLKL antibody for โ€œtotalโ€ MLKL protein isolation (see protocol section on page 2 of the Certificate of Analysis); then use the immunoprecipitated sample to detect the phosphorylated protein using the phospho-MLKL (Ser358) antibody via western blot.
~54 kDa

Immunogen

Epitope: Ser358
Linear peptide corresponding to the Protein Kinase Domain of phospho-MLKL (Ser358).

Application

Western Blot Analysis:
Untreated HT-29 cell lysates or lysates from HT-29 cells treated with Cycloheximide,Z-VAD-FMK and TNF alpha were first immunoprecipitated using the Anti-MLKL โ€œtotalโ€ antibody (1:1000 dilution) to isolate the MLKL protein.
The isolated โ€œtotalโ€ MLKL protein sample was then probed with Anti-phospho-MLKL (Ser358) (1:1000 dilution).
Anti-phospho-MLKL (Ser358) Antibody Set is an antibody set against phospho-MLKL (Ser358) for use in WB.

Biochem/physiol Actions

When used together and under the โ€œRecommended Usageโ€ instructions, this antibody set will detect MLKL phosphorylated at Ser358.

Physical form

100 ยตL of Anti-phospho-MLKL (Ser358) purified polyclonal antibody in 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl, with 0.05% sodium azide.

100 ยตg (concentration: 1 mg/mL) of Anti- MLKL purified polyclonal antibody in 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl, with 0.05% sodium azide.

Analysis Note

Anti- MLKL (Total Antibody): Evaluated by Immunoprecipitation on HT-29 cell lysates.

Anti-phospho-MLKL (Ser358) Antibody: Evaluated by Dot Blot on phosphorylated and non-phosphorylated MLKL peptides.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
One vial of phospho-MLKL (Ser358) antibody

One vial of MLKL โ€œTotalโ€ antibody

์ ํ•ฉํ•œ ์ œํ’ˆ์„ ์ฐพ์„ ์ˆ˜ ์—†์œผ์‹ ๊ฐ€์š”? ย 

๋‹น์‚ฌ์˜ ์ œํ’ˆ ์„ ํƒ๊ธฐ ๋„๊ตฌ.์„(๋ฅผ) ์‹œ๋„ํ•ด ๋ณด์„ธ์š”.

์ €์žฅ ๋“ฑ๊ธ‰

12 - Non Combustible Liquids

flash_point_f

Not applicable

flash_point_c

Not applicable


์‹œํ—˜ ์„ฑ์ ์„œ(COA)

์ œํ’ˆ์˜ ๋กœํŠธ/๋ฐฐ์น˜ ๋ฒˆํ˜ธ๋ฅผ ์ž…๋ ฅํ•˜์—ฌ ์‹œํ—˜ ์„ฑ์ ์„œ(COA)์„ ๊ฒ€์ƒ‰ํ•˜์‹ญ์‹œ์˜ค. ๋กœํŠธ ๋ฐ ๋ฐฐ์น˜ ๋ฒˆํ˜ธ๋Š” ์ œํ’ˆ ๋ผ๋ฒจ์— ์žˆ๋Š” โ€˜๋กœํŠธโ€™ ๋˜๋Š” โ€˜๋ฐฐ์น˜โ€™๋ผ๋Š” ์šฉ์–ด ๋’ค์—์„œ ์ฐพ์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

์ด ์ œํ’ˆ์„ ์ด๋ฏธ ๊ฐ€์ง€๊ณ  ๊ณ„์‹ญ๋‹ˆ๊นŒ?

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ์—์„œ ์ตœ๊ทผ์— ๊ตฌ๋งคํ•œ ์ œํ’ˆ์— ๋Œ€ํ•œ ๋ฌธ์„œ๋ฅผ ์ฐพ์•„๋ณด์„ธ์š”.

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ ๋ฐฉ๋ฌธ

Abdulrahman Allaf et al.
Cold Spring Harbor molecular case studies, 8(4) (2022-06-23)
Schwannomatosis is a rare genetic disorder that predisposes individuals to development of multiple schwannomas mainly in spinal and peripheral nerves and to debilitating chronic pain often unrelated to any schwannoma. Pathogenic variants of two genes, SMARCB1 and LZTR1, are causal
R S Al-Lamki et al.
Cell death & disease, 7(6), e2287-e2287 (2016-07-01)
We previously reported that renal clear cell carcinoma cells (RCC) express both tumor necrosis factor receptor (TNFR)-1 and -2, but that, in organ culture, a TNF mutein that only engages TNFR1, but not TNFR2, causes extensive cell death. Some RCC
Qiong Wang et al.
Translational oncology, 13(2), 372-382 (2019-12-31)
The efficacy of chemotherapeutic agents in killing cancer cells is mainly attributed to the induction of apoptosis. However, the tremendous efforts on enhancing apoptosis-related mechanisms have only moderately improved lung cancer chemotherapy, suggesting that other cell death mechanisms such as

๊ด€๋ จ ์ฝ˜ํ…์ธ 

"Apoptosis & Autophagy in Cancer: Cell Survival by Eluding Cell Death The ability of tumor cells to elude programmed cell death, also known as apoptosis, is a hallmark of most types of cancer. Similary, autophagy is a highly regulated, homeostatic degradative process where cells destroy their own components via the lysosomal machinery and recycle them for prolonged cell survival. Via extensive crosstalk with pro-apoptotic signaling pathways, autophagy can also contribute to cell death and greatly influence general cell health. Elucidating the correlation between autophagy and apoptotic cell death has become the focus of a great deal of research, particularly in tumor biology. On one hand, autophagy may induce cell death by degrading essential components; on the other hand, it may facilitate survival of cancer cells under unfavorable metabolic conditions."

๊ตญ์ œ ๋ฌด์—ญ ํ’ˆ๋ชฉ ๋ฒˆํ˜ธ

SKUGTIN
17-1040004053252934599

์ž์‚ฌ์˜ ๊ณผํ•™์žํŒ€์€ ์ƒ๋ช… ๊ณผํ•™, ์žฌ๋ฃŒ ๊ณผํ•™, ํ™”ํ•™ ํ•ฉ์„ฑ, ํฌ๋กœ๋งˆํ† ๊ทธ๋ž˜ํ”ผ, ๋ถ„์„ ๋ฐ ๊ธฐํƒ€ ๋งŽ์€ ์˜์—ญ์„ ํฌํ•จํ•œ ๋ชจ๋“  ๊ณผํ•™ ๋ถ„์•ผ์— ๊ฒฝํ—˜์ด ์žˆ์Šต๋‹ˆ๋‹ค..

๊ณ ๊ฐ์ง€์›ํŒ€์œผ๋กœ ์—ฐ๋ฝ๋ฐ”๋ž๋‹ˆ๋‹ค.